Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recce PharmaceuticalsASX:RCE -1.30%25 EV-to-EBIT is -4.29 as of Jul. 19, 2026. GuruFocus rates ASX:RCE with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 372 Biotechnology companies, Recce Pharmaceuticals ranks worse than 268816.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Recce Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 was A$198.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-28.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RCE vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Recce Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recce Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Recce Pharmaceuticals's EV-to-EBIT falls into.
Recce Pharmaceuticals's current Enterprise Value is A$124.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-28.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recce Pharmaceuticals (ASX:RCE) has a EV-to-EBIT of -4.29 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Recce Pharmaceuticals and its competitors. According to the industry distribution chart, Recce Pharmaceuticals ranks #999999 out of 372 companies in the Biotechnology industry.
Is Recce Pharmaceuticals' EV-to-EBIT too high?
Recce Pharmaceuticals' current EV-to-EBIT is -4.29. Based on the distribution chart, Recce Pharmaceuticals ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Recce Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #999999 out of 372 companies for EV-to-EBIT. This places Recce Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Recce Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recce Pharmaceuticals's current EV-to-EBIT is -4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current EV-to-EBIT of -4.29. The current EV-to-EBIT is -4.29. Recce Pharmaceuticals' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current EV-to-EBIT is -4.29 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
25GF Score
Get the complete analysis for ASX:RCE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RCE has been successfully added to your 
